MD1813C2 - Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică - Google Patents

Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică Download PDF

Info

Publication number
MD1813C2
MD1813C2 MD96-0306A MD960306A MD1813C2 MD 1813 C2 MD1813 C2 MD 1813C2 MD 960306 A MD960306 A MD 960306A MD 1813 C2 MD1813 C2 MD 1813C2
Authority
MD
Moldova
Prior art keywords
cyclodextrin derivatives
sulphoalkyl
ethers
mixtures
pharmaceutical composition
Prior art date
Application number
MD96-0306A
Other languages
English (en)
Russian (ru)
Other versions
MD1813B2 (ro
Inventor
Valentino J Stella
Роджер РАДЖЕВСКИ
Original Assignee
Канзасский университет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25440795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD1813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Канзасский университет filed Critical Канзасский университет
Publication of MD1813B2 publication Critical patent/MD1813B2/ro
Publication of MD1813C2 publication Critical patent/MD1813C2/ro

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sunt revendicaţi derivaţii purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, în care derivaţii de ciclodextrină sunt prezentaţi cu formula generală:în care n este egal cu 4...6, substituenţii sunt semnificaţi în descriere.De asemenea, sunt revendicaţi un complex clatrat al derivaţilor de ciclodextrină cu diferite substanţe medicamentoase şi o compoziţie farmaceutică pentru administrare orală care conţine complexul menţionat şi un purtător acceptabil farmaceutic.
MD96-0306A 1992-07-27 1993-07-26 Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică MD1813C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/918,702 US5376645A (en) 1990-01-23 1992-07-27 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
PCT/US1993/006880 WO1994002518A1 (en) 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Publications (2)

Publication Number Publication Date
MD1813B2 MD1813B2 (ro) 2001-12-31
MD1813C2 true MD1813C2 (ro) 2002-08-31

Family

ID=25440795

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0306A MD1813C2 (ro) 1992-07-27 1993-07-26 Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică

Country Status (16)

Country Link
US (1) US5376645A (ro)
EP (1) EP0620828B2 (ro)
JP (1) JP3393253B2 (ro)
KR (1) KR100279111B1 (ro)
AT (1) ATE217325T1 (ro)
AU (1) AU672814B2 (ro)
CA (1) CA2119154C (ro)
DE (1) DE69331900T3 (ro)
DK (1) DK0620828T4 (ro)
ES (1) ES2176206T5 (ro)
GE (1) GEP19991649B (ro)
MD (1) MD1813C2 (ro)
PT (1) PT620828E (ro)
RU (1) RU2113442C1 (ro)
TJ (1) TJ275B (ro)
WO (1) WO1994002518A1 (ro)

Families Citing this family (615)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
JP2000509374A (ja) 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
JP4215277B2 (ja) * 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド シクロデキストリンを含有する薬学的組成物用防腐剤系
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
RU2173172C2 (ru) * 1997-05-05 2001-09-10 Сайдекс Инк. Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
PT986403E (pt) * 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
RU2216549C2 (ru) * 1997-11-07 2003-11-20 Дайити Фармасьютикал Ко., Лтд. Пиперазин-циклодекстриновый комплекс и лекарственное средство, содержащее указанный комплекс
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
WO1999042111A1 (en) * 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
JP2002523475A (ja) * 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
ATE356637T1 (de) * 1998-12-04 2007-04-15 California Inst Of Techn Supramolekulare komplexe enthaltende arzneimittel
RU2230062C2 (ru) 1999-01-21 2004-06-10 Бристол-Маерс Сквибб Ко. Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
ES2253364T3 (es) * 2000-03-28 2006-06-01 Farmarc Nederland B.V. Complejos de inclusion de alprazolam y sus composiciones farmaceuticas.
BR0110530A (pt) * 2000-05-02 2003-04-08 Theravance Inc Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
CN100355753C (zh) 2000-05-26 2007-12-19 辉瑞大药厂 用于制备具有治疗作用的莨菪烷衍生物的中间体
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
AU8206401A (en) * 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN100408564C (zh) * 2001-04-10 2008-08-06 美国辉瑞有限公司 治疗hiv的吡唑衍生物
EP1383482B1 (en) * 2001-05-01 2007-07-18 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7008934B2 (en) * 2001-06-28 2006-03-07 Baxter International Inc. Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
CN1522159A (zh) * 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
JP2004536888A (ja) * 2001-07-20 2004-12-09 デイナミート ノーベル ゲゼルシャフト ミット ベシュレンクテル ハフツング エクスプロジーフシュトッフ− ウント ジステームテヒニク 硝酸エステル−シクロデキストリン錯体
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
ES2309294T3 (es) 2002-02-01 2008-12-16 Pfizer Products Inc. Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
EP1476158B1 (en) 2002-02-11 2007-11-14 Pfizer Limited Nicotinamide derivatives useful as pde4 inhibitors
EP1476135A1 (en) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
AR038576A1 (es) * 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
RU2220711C1 (ru) * 2002-04-24 2004-01-10 Закрытое акционерное общество "Брынцалов-А" Противомикробное и противопротозойное средство "трихоброл"
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
RU2220739C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Интраназальное средство
KR101268258B1 (ko) 2002-09-06 2013-05-31 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
BR0314269A (pt) * 2002-09-13 2005-07-26 Cydex Inc Cápsulas contendo composições aquosas de recheio estabilizadas com ciclodextrina derivatizada
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1572173B1 (en) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050100617A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
AU2004206844A1 (en) 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
JP5460947B2 (ja) 2003-09-03 2014-04-02 グラクソ グループ リミテッド 新規調製方法、塩、組成物及び使用
EA009457B1 (ru) 2003-09-03 2007-12-28 Пфайзер Инк. Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
OA13266A (en) 2003-10-03 2007-01-31 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation.
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
CA2551749C (en) * 2003-12-31 2014-02-11 Cydex, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
GEP20094781B (en) 2004-01-22 2009-09-25 Pfizer Sulfonamide derivatives for the treatment of diseases
BRPI0507041A (pt) 2004-01-22 2007-06-12 Pfizer composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
CA2560510C (en) 2004-03-18 2009-10-13 Pfizer Inc. N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
WO2005092840A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Formamide derivatives useful as adrenoceptor
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
DE602005025750D1 (de) 2004-04-15 2011-02-17 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP2030981B1 (en) * 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1758891A2 (en) 2004-06-15 2007-03-07 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
JP4084836B2 (ja) 2004-08-12 2008-04-30 ファイザー・インク ｐ３８ＭＡＰキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
ME01788B (me) 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
DE602005011844D1 (de) 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
ES2549763T3 (es) * 2004-12-07 2015-11-02 Onyx Therapeutics, Inc. Composición para inhibición del proteasoma
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
PT1871353E (pt) * 2005-04-15 2011-03-29 Einstein Coll Med Vitamina k para prevenção e tratamento de irritação de pele secundária a terapia anti-egfr
WO2006111720A2 (en) 2005-04-19 2006-10-26 King's College London Use
TW200716106A (en) * 2005-04-24 2007-05-01 Wyeth Corp Methods for modulating bladder function
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101321742B (zh) 2005-05-26 2012-08-29 神经元系统公司 用于治疗视网膜疾病的组合物和方法
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
ATE456557T1 (de) 2005-06-15 2010-02-15 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
BRPI0616447A2 (pt) 2005-09-30 2011-06-21 Ovation Pharmaceuticals Inc complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
MX383536B (es) 2005-10-26 2025-03-14 Cydex Pharmaceuticals Inc Composiciones de éter sulfoalquílico-ciclodextrina y métodos de preparación de las mismas.
PL1948678T3 (pl) 2005-11-09 2013-09-30 Onyx Therapeutics Inc Związki do hamowania enzymów
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
JP2009520821A (ja) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー 肺内沈着の増大を有するコルチコステロイドを送達するための方法およびシステム
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
US20070191327A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Sterilization of corticosteroids with reduced mass loss
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
MX2008012105A (es) * 2006-03-24 2008-10-03 Wyeth Corp Metodos para modular la funcion de la vejiga.
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
JP2009531436A (ja) * 2006-03-24 2009-09-03 ワイス 認知障害および他の障害の治療方法
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
MX2008013405A (es) 2006-04-18 2009-03-09 Ekr Therapeutics Inc Composiciones farmaceuticas premezcladas listas para uso.
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CN100374468C (zh) * 2006-05-25 2008-03-12 重庆通量精细化工有限公司 水溶性磺烷基醚-β-环糊精的合成工艺
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
EP2043685B1 (en) * 2006-07-03 2015-12-23 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
US20080207731A1 (en) 2006-08-23 2008-08-28 Intellect Neurosciences, Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2061458B1 (en) * 2006-09-15 2014-12-10 Regents of the University of Minnesota Topiramate compositions and methods for their use
EP2380566A3 (en) 2006-09-15 2012-04-11 Stevia APS Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol
BRPI0717102A2 (pt) 2006-09-21 2013-10-29 Raqualia Pharma Inc Derivados de benzimidazol como inibidores seletivos de bomba de ácido
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
HRP20110158T1 (hr) 2006-10-18 2011-04-30 Pfizer Products Inc. Biaril eterski spojevi ureje
MY150649A (en) 2006-10-20 2014-02-14 Icos Corp Compositions of chk1 inhibitors
ES2368460T3 (es) 2006-10-23 2011-11-17 Pfizer Inc. Compuestos de fenilmetil biciclocarboxiamida sustituidos.
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
AU2007321977A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
SI2115126T1 (sl) 2007-03-02 2015-06-30 Wyeth Llc Uporaba bakra in glutamata v celični kulturi za proizvodnjo polipeptidov
ATE530188T1 (de) * 2007-03-02 2011-11-15 Univ Wollongong Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
SI2152078T1 (sl) * 2007-04-27 2021-08-31 Cydex Pharmaceuticals, Inc. Formulacije, ki vsebujejo klopidogrel in sulfoalkilni eter ciklodekstrina in metode uporabe
AU2015255164B2 (en) * 2007-04-27 2017-06-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
EP2148692B1 (en) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
KR100929920B1 (ko) * 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
MX2010002518A (es) 2007-09-05 2010-03-26 Pfizer Ltd Sal xinafoato de n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-on)-6-il] -5-fluoro-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]-2,4-pirimid indiamina.
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US8054177B2 (en) * 2007-12-04 2011-11-08 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US20110224232A1 (en) * 2008-05-06 2011-09-15 Board Of Regents, The University Of Texas System Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
JP5643195B2 (ja) * 2008-06-16 2014-12-17 デビオファーム インターナショナル ソシエテ アノニム 濃縮オキサリプラチン溶液及びその調製方法
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
PE20120029A1 (es) 2008-11-15 2012-02-13 Rib X Pharmaceuticals Inc Composiciones antimicrobianas
WO2010058858A1 (ja) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
CN102348697B (zh) 2009-01-12 2014-12-10 辉瑞股份有限公司 磺酰胺衍生物
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
TWI453029B (zh) 2009-01-14 2014-09-21 Novacta Biosystems Ltd 去氧艾克特卡丁b(deoxyactagardine b), 包含其之醫藥組合物及其製造方法
SG173504A1 (en) 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
AU2010252609A1 (en) 2009-05-29 2011-11-10 Pfizer Limited Novel glucocorticoid receptor agonists
EA022890B1 (ru) 2009-05-29 2016-03-31 Сидекс Фармасьютикалз, Инк. Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
SG181997A1 (en) 2010-01-21 2012-08-30 Goodchild Invest Pty Ltd Anaesthetic formulation
EP2531519A1 (en) 2010-02-02 2012-12-12 Novacta Biosystems Limited Lantibiotic salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2552927C2 (ru) * 2010-03-13 2015-06-10 Истпонд Лабораториз Лимитед Жиросвязывающая композиция
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
BR112012030014B1 (pt) 2010-05-26 2021-07-13 Neurophyxia B.V. Formulações aquosas solúveis de 2-iminobiotina
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
EP2579869A2 (en) * 2010-06-11 2013-04-17 Baxter International Inc Formulations including amiodarone and salts thereof and methods of their manufacture and use
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
WO2012004706A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
CN103154012B (zh) 2010-08-24 2015-11-25 英皇创新有限公司 聚丙基醚亚胺的糖树状聚体
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012061409A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
HUE037660T2 (hu) 2011-01-26 2018-09-28 Allergan Inc Androgén készítmény szembetegség kezelésére
WO2012148548A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
JP5595616B2 (ja) 2011-04-05 2014-09-24 ファイザー・リミテッド トロポミオシン関連キナーゼ阻害薬としてのピロロ［２，３−ｄ］ピリミジン誘導体
MX350024B (es) 2011-05-18 2017-08-23 Raqualia Pharma Inc Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
RU2566262C2 (ru) 2011-06-15 2015-10-20 Синтон Бв Стабилизированная композиция вориконазола
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
JP5898767B2 (ja) 2011-07-13 2016-04-06 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ エンケファリン類似体
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AU2012291744A1 (en) 2011-08-02 2014-02-20 Pfizer Inc. Crizotinib for use in the treatment of cancer
EP2739274A1 (en) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Treatment of cognitive impairment
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
PL2758052T3 (pl) 2011-09-18 2018-10-31 Euro-Celtique S.A. Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
EP2771335A2 (en) 2011-10-26 2014-09-03 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
EP3243815B1 (en) 2011-10-28 2019-07-10 Inhibitaxin Limited Pyridazine derivatives useful in therapy
JP6058023B2 (ja) 2011-12-15 2017-01-11 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ スルホンアミド誘導体
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
HK1211311A1 (en) 2012-02-28 2016-05-20 锡德克斯药物公司 Alkylated cyclodextrin compositions and processes for preparing and using the same
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
US20150087822A1 (en) 2012-03-30 2015-03-26 Sapiotec Gmbh Anthocyanidin complex
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
US20150216895A1 (en) 2012-08-03 2015-08-06 The United States of America, as represented by the Secretary, Department of Health & Human Servic Cyclodextrin for the treatment of lysosomal storage diseases
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
CA2884921A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
CA2885247A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
CA2887057A1 (en) * 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin complex for the treatment of multiple myeloma
MX360192B (es) 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
MD20150037A2 (ro) 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
CA2890009C (en) 2012-11-08 2017-11-28 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP2919791B1 (de) * 2012-11-15 2017-03-22 SapioTec GmbH Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
WO2014080633A1 (en) 2012-11-21 2014-05-30 Raqualia Pharma Inc. Polymorph forms
KR101745225B1 (ko) 2012-12-03 2017-06-08 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절인자
KR20150107742A (ko) * 2012-12-11 2015-09-23 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
ES2694787T3 (es) 2013-02-21 2018-12-27 Pfizer Inc. Formas sólidas de un inhibidor selectivo de CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
RU2021111681A (ru) 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применение
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3719030B1 (en) 2013-04-17 2024-07-10 Sage Therapeutics, Inc. 19-nor neuroactive steroids for inducing sedation
IL310348A (en) 2013-04-17 2024-03-01 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
HUE062265T2 (hu) 2013-06-27 2023-10-28 Pfizer Heteroaromás vegyületek és azok alkalmazása dopamin D1 ligandumokként
HK1223825A1 (zh) 2013-07-08 2017-08-11 Abbvie Inc. 包含阿曲生坦的稳定化药物剂型
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RU2572334C2 (ru) * 2013-12-06 2016-01-10 Общество С Ограниченной Ответственностью "Луфатен" Клатратный комплекс арабиногалактана или гуммиарабика с 20-гидроксиэкдизоном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
JP2016540811A (ja) 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
CN104971355B (zh) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
MX2016013968A (es) 2014-04-25 2016-11-15 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
CA2946475A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
GEP20186921B (en) 2014-05-14 2018-11-12 Pfizer Pyrazolopyridines and pyrazolopyrimidines
SG11201608320QA (en) 2014-05-15 2016-11-29 Pfizer Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
TWI672300B (zh) 2014-05-20 2019-09-21 日商拉夸里亞創藥股份有限公司 苯并異唑衍生物鹽類
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US20180179247A1 (en) 2014-05-29 2018-06-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
EP3148992A1 (en) 2014-05-30 2017-04-05 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
DK3157915T3 (en) 2014-06-17 2019-04-23 Pfizer Substituted dihydroisoquinolinone compounds
PL3166642T3 (pl) 2014-06-18 2020-11-30 Audevard Transdermalne preparaty pergolidu i ich zastosowanie
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
DK3183295T3 (da) 2014-08-22 2023-08-21 Cydex Pharmaceuticals Inc Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
IL292465B2 (en) 2014-10-07 2025-06-01 Sage Therapeutics Inc Neuroactive compounds and methods of use thereof
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
KR102612943B1 (ko) 2014-10-16 2023-12-13 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
SMT202000276T1 (it) 2014-11-27 2020-07-08 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
BR112017015536B1 (pt) 2015-01-22 2021-05-18 Phytoplant Research S.L métodos de purificação de canabinoides
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
CN107427003B (zh) 2015-02-02 2023-01-31 梅制药公司 联合治疗
CN107427458A (zh) 2015-02-06 2017-12-01 马瑞纳斯制药公司 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
JP6971963B2 (ja) 2015-03-19 2021-11-24 サイデックス・ファーマシューティカルズ・インコーポレイテッド シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20160361345A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl Beta-Cyclodextrin Compositions and Methods
EP3319610A4 (en) 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
KR20240166589A (ko) 2015-07-06 2024-11-26 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
ES2865258T3 (es) 2015-07-06 2021-10-15 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
WO2017007805A1 (en) 2015-07-09 2017-01-12 Gilead Sciences, Inc. Intravenous formulations of a late sodium current inhibitor
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
SG11201803489SA (en) 2015-12-10 2018-06-28 Pfizer Ltd 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
KR102687603B1 (ko) 2015-12-24 2024-07-24 다케다 야쿠힌 고교 가부시키가이샤 공결정, 이의 제조방법 및 공결정을 함유하는 의약
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
CN108884093B (zh) 2016-01-15 2021-07-09 辉瑞公司 一种多巴胺d3配体化合物
US20170239323A1 (en) 2016-02-18 2017-08-24 The Medicines Company Oritavancin formulations
MX2018010292A (es) 2016-02-28 2018-09-27 Aldeyra Therapeutics Inc Tratamiento de condiciones oculares alergicas con ciclodextrinas.
EP3426772A4 (en) 2016-03-09 2019-08-28 Beijing Percans Oncology Co. Ltd. TUMOR CELLSUSPENSION CULTURES AND RELATED METHODS
JP7305352B2 (ja) * 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP7116490B2 (ja) 2016-05-09 2022-08-10 アルデイラ セラピューティクス， インコーポレイテッド 眼の炎症性障害および疾患の組合せ処置
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
EP3919502A1 (en) 2016-07-07 2021-12-08 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
WO2018020358A1 (en) 2016-07-29 2018-02-01 Pfizer Inc. Cyclic peptides as c5 a receptor antagonists
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
MA45920B1 (fr) 2016-08-15 2021-08-31 Pfizer Inhibiteurs de pyridopyrimidinone cdk2/4/6
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US11306075B2 (en) 2016-12-20 2022-04-19 Oligomerix, Inc. Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
WO2018118791A2 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
EP3553056B1 (en) 2017-01-20 2021-02-17 Shenzhen TargetRx, Inc. (hetero)arylamide compound for inhibiting protein kinase activity
US10875853B2 (en) 2017-01-20 2020-12-29 Shenzhen Targetrx, Inc. (Hetero)arylamide compound for inhibiting protein kinase activity
JP2020506899A (ja) 2017-01-20 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体
RU2726631C1 (ru) 2017-01-23 2020-07-15 Пфайзер Инк. Гетероциклические спиросоединения в качестве ингибиторов magl
WO2018146698A1 (en) 2017-02-07 2018-08-16 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
EP3596040B1 (en) 2017-03-16 2023-10-11 Aldeyra Therapeutics, Inc. Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
US12428423B2 (en) 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
EP3618825A4 (en) 2017-05-03 2021-01-20 Cydex Pharmaceuticals, Inc. COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
PE20200696A1 (es) 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
WO2019001383A1 (zh) 2017-06-26 2019-01-03 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
JP6928986B2 (ja) 2017-06-26 2021-09-01 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
JP7233743B2 (ja) 2017-08-11 2023-03-07 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物
TWI808092B (zh) 2017-08-30 2023-07-11 中國大陸商北京軒義醫藥科技有限公司 作為干擾素基因調節劑之刺激劑的環狀二核苷酸
CN111518082B (zh) 2017-08-30 2021-09-17 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20210009613A1 (en) 2017-12-12 2021-01-14 Shenzhen Targetrx, Inc. Arylphosphine oxides for inhibiting kinase activity
JP7043098B2 (ja) 2017-12-21 2022-03-29 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジアニリノピリミジン系化合物
US11447512B2 (en) 2017-12-21 2022-09-20 Shenzhen Targetrx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
EP3719027A4 (en) 2017-12-21 2020-12-16 Shenzhen TargetRx, Inc. NEW NUCLEOSIDIC INHIBITOR OF ANTIVIRAL REVERSE TRANSCRIPTASE
CA3086299A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
KR20200104349A (ko) 2017-12-22 2020-09-03 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN111788171A (zh) 2018-01-29 2020-10-16 菲拓普兰特研究公司 使用液：液色谱法纯化大麻素的方法
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
TWI741268B (zh) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
WO2019201194A1 (zh) 2018-04-16 2019-10-24 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
CN113956269A (zh) 2018-04-16 2022-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
GEAP202215475A (en) 2018-04-26 2022-07-11 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
JP7541512B2 (ja) 2018-05-30 2024-08-28 コンバート ファーマシューティカルズ エス．エー． プロドラッグおよびその医学的使用
BR112020024301A2 (pt) 2018-06-01 2021-02-23 Bayer Cropscience Lp composição fungicida estabilizada compreendendo ciclodextrina
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
CN110194772B (zh) 2018-07-02 2022-04-05 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
US12076320B2 (en) 2018-07-12 2024-09-03 Shenzhen Targetrx, Inc. Diarylpyrazole compound, composition comprising same, and use thereof
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
MX2021000549A (es) 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
WO2020073862A1 (zh) 2018-10-10 2020-04-16 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
CN113166193B (zh) 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
AR116771A1 (es) 2018-10-19 2021-06-09 Sage Therapeutics Inc Los neuroesteroides activos y sus métodos de uso
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CR20210284A (es) 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina
WO2020118060A1 (en) 2018-12-05 2020-06-11 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12129266B2 (en) 2018-12-06 2024-10-29 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020120482A1 (en) 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
AU2019402158B2 (en) 2018-12-18 2025-07-03 Mundipharma International Corporation Limited Compounds for treating lymphoma or a T-cell malignant disease
WO2020125391A1 (zh) 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
TWI892697B (zh) 2018-12-21 2025-08-01 美商賽吉醫療公司 神經活性類固醇及其組合物
WO2020141226A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
CA3123718A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
JP7340023B2 (ja) 2019-01-14 2023-09-06 ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド テトラゾロン置換ステロイド及びその使用
MX2021008866A (es) 2019-01-23 2021-08-19 Pfizer Forma de polimorfo de sal de hidrato de monofosfato de un derivado conocido de tetra hidroisoquinolina.
AU2020213761C1 (en) 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
CN111574521A (zh) 2019-02-18 2020-08-25 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
JP7241435B2 (ja) 2019-02-27 2023-03-17 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾール系化合物および該当化合物を含む組成物並びにその使用
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
CN120535477A (zh) 2019-04-29 2025-08-26 索伦特治疗有限责任公司 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
PH12021553005A1 (en) 2019-05-31 2023-08-14 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN112047938B (zh) 2019-06-06 2022-11-22 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
BR112021026445A2 (pt) 2019-06-27 2022-03-08 Sage Therapeutics Inc Composições e métodos para tratar distúrbios de cns
EP3990467A1 (en) 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7787635B2 (ja) 2019-06-27 2025-12-17 セージ セラピューティクス， エルエルシー Ｃｎｓ障害を治療するための組成物及び方法
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021014415A2 (en) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
US20230000997A1 (en) 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
US20220306659A1 (en) 2019-08-23 2022-09-29 Beijing Tide Pharmaceutical Co., Ltd. Compound inhibiting and inducing degradation of egfr and alk
AR119971A1 (es) 2019-09-16 2022-01-26 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
AU2020355343B2 (en) 2019-09-25 2023-11-30 Pfizer Inc. Polyheterocyclic modulators of STING (stimulator of interferon genes)
CA3151355C (en) 2019-09-26 2024-02-20 Yihan Wang Substituted aromatic fused ring derivative and composition comprising same, and use thereof
KR102818791B1 (ko) 2019-11-01 2025-06-11 상하이테크 유니버시티 Eed 억제제, 및 이의 제조방법 및 용도
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN114829364B (zh) 2019-12-16 2023-08-22 北京泰德制药股份有限公司 抑制并诱导降解egfr激酶的化合物
US20230122967A1 (en) 2020-01-17 2023-04-20 Shengke Pharmaceuticals (Jiangsu) Ltd. Novel compounds as inhibitors of pcsk9
AU2021219370A1 (en) 2020-02-12 2022-08-25 Curadev Pharma Pvt. Ltd. Small molecule STING antagonists
CN115551874A (zh) 2020-03-18 2022-12-30 萨奇治疗股份有限公司 神经活性类固醇及其使用方法
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactemic agents and their use as inhibitors of hpk1
MY210588A (en) 2020-05-04 2025-10-01 Takeda Pharmaceuticals Co Luminally-acting n-(piperidin-4-yl)benzamide derivatives
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
US20230212160A1 (en) 2020-05-20 2023-07-06 Beijing Tide Pharmaceutical Co., Ltd. 2,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitors
CA3183248A1 (en) 2020-06-24 2021-12-30 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
KR20250103811A (ko) 2020-06-30 2025-07-07 리유니온 뉴로사이언스 인코포레이티드 트립타민 전구약물
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
WO2022012484A1 (zh) 2020-07-13 2022-01-20 北京泰德制药股份有限公司 作为atr激酶抑制剂的吡唑并嘧啶化合物
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022013691A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
CN116096721B (zh) 2020-08-27 2026-01-09 晟科药业（江苏）有限公司 作为新型选择性flt3抑制剂的1h-咪唑并[4,5-h]喹唑啉化合物
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
CN116710090A (zh) 2020-10-09 2023-09-05 Napa医疗有限公司 Cd38的杂芳基酰胺抑制剂
AU2021385335A1 (en) 2020-11-25 2023-06-29 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CA3213593A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
JP2024516359A (ja) 2021-04-07 2024-04-15 ライフアーク Ｕｌｋ１／２阻害剤およびその使用
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
MX2023015139A (es) 2021-06-26 2024-01-22 Array Biopharma Inc Inhibidores de mutacion de her2.
PE20240780A1 (es) 2021-07-28 2024-04-17 Sage Therapeutics Inc Formas cristalinas de un esteroide neuroactivo
WO2023017451A1 (en) 2021-08-11 2023-02-16 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
JP2024529089A (ja) 2021-08-11 2024-08-01 キュラデブ ファーマ ピーブイティー． リミテッド Ｓｔｉｎｇアンタゴニストとしての小分子ウレア誘導体
JP2024534558A (ja) 2021-09-22 2024-09-20 セージ セラピューティクス， インコーポレイテッド 重水素化ｎｍｄａ正調節化合物及びその使用方法
AU2022399786A1 (en) 2021-12-01 2024-07-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
KR20240134949A (ko) 2022-01-17 2024-09-10 수조우 푸허 바이오파마 컴퍼니 리미티드 Egfr 억제제 역할을 하는 2-피페리딜 또는 2-피라졸릴 치환된 피리미딘 화합물
US20250127737A1 (en) * 2022-01-25 2025-04-24 Leiutis Pharmaceuticals Llp Novel naproxen sodium preparations for parenteral administration
IL315052A (en) 2022-02-18 2024-10-01 Beren Therapeutics P B C Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023165570A1 (zh) 2022-03-03 2023-09-07 深圳市塔吉瑞生物医药有限公司 环烷基或杂环基取代的杂芳基化合物及其组合物及用途
JP2025511255A (ja) 2022-03-30 2025-04-15 武田薬品工業株式会社 Ｎ－（ピロリジン－３－イルまたはピペリジン－４－イル）アセトアミド誘導体
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
KR20250004248A (ko) 2022-04-15 2025-01-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Egfr 분해제
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
EP4332087A1 (en) 2022-04-29 2024-03-06 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticles
CN116969851A (zh) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
AU2023316601A1 (en) 2022-07-28 2025-02-13 Beijing Earthwise Technology Co., Ltd. Prmt5 inhibitors
EP4562017A1 (en) 2022-07-29 2025-06-04 Pfizer Inc. Novel acc inhibitors
AR130151A1 (es) 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
CN120513245A (zh) 2022-11-15 2025-08-19 克拉德夫制药有限公司 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂
JP2025538551A (ja) 2022-11-21 2025-11-28 セージ セラピューティクス， エルエルシー 負のｎｍｄａ調節化合物及びその使用方法
WO2024120464A1 (zh) 2022-12-09 2024-06-13 深圳市塔吉瑞生物医药有限公司 核苷酸类似物及其组合物及用途
KR20250117449A (ko) 2022-12-23 2025-08-04 제지앙 양리 파마슈티칼 테크놀로지 씨오., 엘티디. Parp1 억제제
JP2026502971A (ja) 2022-12-30 2026-01-27 蘇州浦合医薬科技有限公司 Ｗｒｎ阻害剤
WO2024140923A1 (zh) 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
PE20252398A1 (es) 2023-01-17 2025-10-10 Suzhou Puhe Biopharma Co Ltd Inhibidores de prmt5-mta
EP4653426A1 (en) 2023-01-20 2025-11-26 Beijing Tide Pharmaceutical Co., Ltd. Proteolysis targeting chimera compound
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
TW202506678A (zh) 2023-04-14 2025-02-16 日商武田藥品工業股份有限公司 雜環化合物
WO2024229297A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Lymphatic system-targeting compounds
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer
WO2024251159A1 (zh) 2023-06-06 2024-12-12 华领医药技术（上海）有限公司 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025007863A1 (zh) 2023-07-03 2025-01-09 深圳市塔吉瑞生物医药有限公司 1H-吡唑并[4,3-c]吡啶化合物及其组合物及用途
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025221732A1 (en) 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof
WO2025221731A1 (en) 2024-04-15 2025-10-23 Sage Therapeutics, Inc. Nmda receptor-modulating compounds and methods of use thereof
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025250816A1 (en) 2024-05-29 2025-12-04 Sage Therapeutics, Inc. Agents for delivering nmda receptor modulating compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535152A (en) * 1983-02-14 1985-08-13 Chinoin, Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (ro) * 1970-06-10 1975-02-04
DE3270055D1 (en) * 1981-01-23 1986-04-30 Wellcome Found Chemical complex
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535152A (en) * 1983-02-14 1985-08-13 Chinoin, Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Water soluble cyclodextrin polymers substituted by ionic groups and process for the preparation thereof
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives

Also Published As

Publication number Publication date
AU672814B2 (en) 1996-10-17
PT620828E (pt) 2002-10-31
DE69331900T2 (de) 2003-01-16
DK0620828T3 (da) 2002-08-26
EP0620828B1 (en) 2002-05-08
DK0620828T4 (da) 2008-11-03
TJ275B (en) 2000-10-05
KR100279111B1 (ko) 2001-03-02
ATE217325T1 (de) 2002-05-15
AU4779993A (en) 1994-02-14
US5376645A (en) 1994-12-27
JPH06511513A (ja) 1994-12-22
EP0620828A1 (en) 1994-10-26
EP0620828A4 (en) 1996-05-15
RU2113442C1 (ru) 1998-06-20
MD1813B2 (ro) 2001-12-31
DE69331900T3 (de) 2009-03-26
EP0620828B2 (en) 2008-07-09
ES2176206T3 (es) 2002-12-01
ES2176206T5 (es) 2008-12-01
GEP19991649B (en) 1999-06-14
CA2119154C (en) 1998-06-16
DE69331900D1 (de) 2002-06-13
WO1994002518A1 (en) 1994-02-03
JP3393253B2 (ja) 2003-04-07
CA2119154A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
MD1813C2 (ro) Derivaţi purificaţi de ciclodextrină ai eterilor sulfoalchilici sau amestecurile lor, complex clatrat al derivaţilor de ciclodextrină cu conţinut de medicament şi compoziţie farmaceutică
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
TR199500856A2 (tr) Nefesle ice cekilerek alinan farmasötik bilesim.
DE69328192D1 (de) Injizierbare Arzneizubereitungen enthaltend Taxanderivate
MY118371A (en) Tetrahydrolipstatin containing compositions
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
CA2227887A1 (en) Pharmaceutical compositions of conjugated estrogens and methods for their use
NZ312715A (en) Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
AU3912493A (en) A pharmaceutical composition containing a defined lipid system
HUT67661A (en) New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
AU1665992A (en) Novel taurine-based pharmaceutical composition for administration by inhalation
ATE204474T1 (de) Amethocain enthaltende arzneimittel
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
GB1488995A (en) Compositions containing anti-androgenic compounds
AU3595689A (en) Anthracycline derivatives having cytostatic activity
IL147901A0 (en) Phenanthroline-7-one derivatives and their therapeutic uses
MX9601852A (es) Formulaciones de estramustina con propiedades farmaceuticas mejoradas.
GB1491358A (en) Pharmaceutical materials
JO1531B1 (en) New near-compounds
AR029631A1 (es) USO DE UN DERIVADO BENZO[D](1,3)-OXAZIN-2-ONA PARA PREPARAR UN MEDICAMENTO Y UN KIT FARMACÉUTICAMENTE uTIL ADAPTADO PARA LA ADMINISTRACIoN ORAL DIARIA

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)